Relmada Therapeutics (RLMD) Other Non-Current Liabilities (2014 - 2026)
Relmada Therapeutics (RLMD) reported Other Non-Current Liabilities of $3.7 million for Q1 2026, up 365.81% year-over-year from $802590.0 in Q1 2025, and up 252.39% on a QoQ basis from $1.1 million in Q4 2025.
Relmada Therapeutics (RLMD) has 8 years of Other Non-Current Liabilities data on file, last reported at $3.7 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 365.81% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 365.81% YoY) and the FY2025 annual result came in at $1.1 million, up 23650.41% from the prior year.
- Other Non-Current Liabilities improved to $3.7 million in Q1 2026 per RLMD's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.7 million in Q1 2026 and bottomed at $4467.0 in Q4 2024.
- The 3-year median for Other Non-Current Liabilities is $221107.0 (2025), against an average of $838908.0.
- The widest annual swing landed in 2025, when Other Non-Current Liabilities soared 23650.41%; it then jumped 365.81% in 2026.
- Tracing RLMD's Other Non-Current Liabilities over 3 years: stood at $4467.0 in 2024, then soared by 23650.41% to $1.1 million in 2025, then jumped by 252.39% to $3.7 million in 2026.
- Per Business Quant, the three latest RLMD Other Non-Current Liabilities figures stand at $3.7 million (Q1 2026), $1.1 million (Q4 2025), and $221107.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.74 Mn |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 221,107.00 |
| Jun 30, 2025 | 32,116.00 |
| Mar 31, 2025 | 802,590.00 |
| Dec 31, 2024 | 4,467.00 |
| Sep 30, 2024 | 12,562.00 |
| Jun 30, 2018 | 4.19 Mn |
| Jun 30, 2017 | 175,853.00 |
| Mar 31, 2017 | 139,421.00 |
| Dec 31, 2016 | 137,078.00 |
| Sep 30, 2016 | 134,736.00 |
| Jun 30, 2016 | 892,503.00 |
| Mar 31, 2016 | 108,985.00 |
| Jun 30, 2015 | 14.00 Mn |
| Mar 31, 2015 | 100,000.00 |
| Dec 31, 2014 | 100,000.00 |
| Jun 30, 2014 | 25.59 Mn |